![]() |
![]() | ![]() |
We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
![]()
Sequenom seeks to shed light on the genetic underpinnings of life for uses in industrial genomics. Sequenom's MassArray technology uses mass spectrometry to analyze variations in DNA (the most common are called single nucleotide polymorphisms) to determine which ones have an impact on human health, agricultural yields, or livestock production. The company's Genolyzer software analyzes genotype samples. Its SpectroCHIP silicon wafers are used with the MassArray system to analyze biomolecules. Sequenom is beta testing its technology at Genzyme, the US Department of Agriculture, and the National Institutes of Health, among others. Sequenom is going to have its IPO this week. I think Sequenom has better technology than Affymetrix. Thus, I believe it will equal or surpass the valuation of Affymetrix.
| ||||||||||||||
|
Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
© 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |